Literature DB >> 3974774

Studies of bone morphology, bone densitometry and laboratory data in patients on maintenance hemodialysis treatment.

B Lindergård, O Johnell, B E Nilsson, P E Wiklund.   

Abstract

Bone morphological parameters of renal osteodystrophy such as abundance of osteoid surface, osteoid seam width index, calcification fronts, osteoclast activity and trabecular bone volume were studied in 71 patients on maintenance hemodialysis and compared with bone densitometry, laboratory and clinical data. Increased osteoclast activity (hyperparathyroidism) was by far the most common bone morphological finding. Patients with chronic pyelonephritis or polycystic kidney disease had more than double the amount of osteoid than patients with chronic glomerulonephritis. The trabecular bone volume seemed to be increased in most patients in contrast to the cortical bone volume which was decreased, judged from bone densitometry and previously from X-ray. Despite that patients with polycystic kidney disease were older, their trabecular volume was larger than in patients with glomerulonephritis. The bone mineral content evaluated by bone densitometry was low in most patients, and more associated with bone morphological signs of osteomalacia than with secondary hyperparathyroidism. Serum phosphate (S-PO4) and serum parathyroid hormone (S-PTH) seemed to discriminate better between osteomalacia and secondary hyperparathyroidism than serum alkaline phosphatase (S-Alk. phosph.), which was elevated in both groups. Patients who had been bilaterally nephrectomized were no more abnormal than other patients, and they had lower S-Alk. phosph. The abundance of osteoclasts was found to be a predictor of future development of clinical secondary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3974774     DOI: 10.1159/000183355

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  12 in total

Review 1.  Renale osteodystrophie.

Authors:  Daniel Cejka
Journal:  Wien Med Wochenschr       Date:  2013-05-09

Review 2.  Osteoporosis and atherosclerosis in chronic renal failure.

Authors:  Y Nishizawa; H Morii
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients.

Authors:  Jong Chan Park; Csaba P Kovesdy; Uyen Duong; Elani Streja; Mehdi Rambod; Allen R Nissenson; Stuart M Sprague; Kamyar Kalantar-Zadeh
Journal:  Hemodial Int       Date:  2010-03-24       Impact factor: 1.812

Review 4.  Physiological mechanisms and therapeutic potential of bone mechanosensing.

Authors:  Zhousheng Xiao; Leigh Darryl Quarles
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

Review 5.  Update on the role of bone biopsy in the management of patients with CKD-MBD.

Authors:  P Evenepoel; G J S Behets; M R Laurent; P C D'Haese
Journal:  J Nephrol       Date:  2017-08-22       Impact factor: 3.902

Review 6.  Chronic kidney disease and bone fracture: a growing concern.

Authors:  Thomas L Nickolas; Mary B Leonard; Elizabeth Shane
Journal:  Kidney Int       Date:  2008-06-18       Impact factor: 10.612

7.  Femoral bone mineral density reflects histologically determined cortical bone volume in hemodialysis patients.

Authors:  T Adragao; J Herberth; M-C Monier-Faugere; A J Branscum; A Ferreira; J M Frazao; H H Malluche
Journal:  Osteoporos Int       Date:  2009-06-25       Impact factor: 4.507

8.  The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study.

Authors:  B Ghosh; T Brojen; S Banerjee; N Singh; S Singh; O P Sharma; J Prakash
Journal:  Indian J Nephrol       Date:  2012-07

Review 9.  Osteoporosis in the elderly with chronic kidney disease.

Authors:  F Fevzi Ersoy
Journal:  Int Urol Nephrol       Date:  2006-11-11       Impact factor: 2.266

10.  Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy.

Authors:  Hiroaki Ishida; Hirotaka Komaba; Naoto Hamano; Hideyuki Yamato; Kaichiro Sawada; Takehiko Wada; Michio Nakamura; Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2020-03-05       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.